The FDA approved the combination use of Adcetris with chemotherapy for previously untreated stage III or stage IV classical Hodgkin Lymphoma in adults, marking the fifth FDA approval for the drug.

The agency’s decision is based on the successful clinical trial results from a five-year Phase 3 ECHELON-1 clinical trial that compared Adcetris (Brentuximab vedotin) plus AVD (Adriamycin, vinblastine and dacarbazine) to ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine).

It is the first FDA approved regimen in frontline stage III or stage IV classical Hodgkin Lymphoma in more than 40 years.